Abstract Introductions and objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the ...

Abstract Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and dietary supplements) is an uncommon cause of liver disease presenting with a wide range of phenotypes and disease severity, ...

Abstract in English, Spanish The clinical management of hepatitis C virus (HCV) infection presents several challenges today. WHO's goal is to eliminate it by 2030. It is an ambitious goal and difficult to meet given the ...

Abstract Background and aims: Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking. Approach and results: We performed a retrospective study on patients with AIH and COVID-19 from ...

Comment J Viral Hepat . 2021 Feb;28(2):446-447. doi: 10.1111/jvh.13433. Epub 2020 Nov 18. Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection Ezequiel Ridruejo 1 2 3, Federico Piñero 2 ...

The development of consortia has been useful for exploring challenging scenarios and uncharted territories in liver disease treatments. Several consortia already developed in the United States and Europe have become key ...

Abstract Acute liver failure is a critical medical condition defined as rapid development of hepatic dysfunction associated with encephalopathy. The prognosis in these patients is highly variable and depends on the ...